Leukemia & Lymphoma Society

FDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE

Retrieved on: 
金曜日, 6月 14, 2024
ECOG, NIH, Amgen, Leukemia, Development, Patient, Research, B-ALL, National Cancer Institute, Blinatumomab, Risk, MRD, Recurrence, University, Research and development, Death, FDA, Acute lymphoblastic leukemia, NCI, Food, ALL, OS, Leukemia & Lymphoma Society, AMGN, Bangladesh Technical Education Board, Pharmaceutical industry

THOUSAND OAKS, Calif., June 14, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.

Key Points: 
  • BLINCYTO has helped thousands of patients with B-ALL over the last 10 years.
  • Study results demonstrated that BLINCYTO added to multiphase consolidation chemotherapy showed superior overall survival (OS) versus chemotherapy alone.
  • ECOG-ACRIN sponsored the trial with public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH).
  • In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement.

The Leukemia & Lymphoma Society and Tasso Announce Partnership to Advance Blood Cancer Research

Retrieved on: 
木曜日, 5月 30, 2024
Oncology, Health, Other Science, General Health, Clinical Trials, Research, Science, Partnership, Patient, Bone marrow, LLS, Clinical trial, Leukemia & Lymphoma Society, Doctor of Philosophy, Travel, Lymphoma, Immunodeficiency, CBC, Beat, Leukemia, Complete blood count, Entrepreneurship

The Leukemia & Lymphoma Society® (LLS), a global leader in the fight against blood cancer, and Tasso, Inc. , the leading provider of patient-centric, clinical grade blood collection solutions, today announced a collaboration to accelerate blood cancer research.

Key Points: 
  • The Leukemia & Lymphoma Society® (LLS), a global leader in the fight against blood cancer, and Tasso, Inc. , the leading provider of patient-centric, clinical grade blood collection solutions, today announced a collaboration to accelerate blood cancer research.
  • Frequent clinic visits and venipuncture blood draws are a burden on patients with leukemia, lymphoma, and other blood cell disorders.
  • To reduce the burden on blood cancer patients, LLS and Tasso are collaborating on a clinical trial evaluating a new patient-centric strategy for collecting critical Complete Blood Count (CBC) using the Tasso device in blood cancer patients with low blood counts.
  • “As a true patient-centric organization, The Leukemia & Lymphoma Society seeks out innovations that can make receiving care easier for blood cancer patients,” said Ashley Yocum, Ph.D., Executive Research Strategy Lead of the Beat AML® Master Clinical Trial at LLS.

Physicians’ Education Resource® to host symposia at the 2024 Annual Oncology Meeting

Retrieved on: 
木曜日, 5月 23, 2024
Patient, Faculty, Pharmacist, Health, Practitioner, Cancer, PER, Lung cancer, Nursing, CME, American Cancer Society, Physician, Leukemia & Lymphoma Society, Oncology

CRANBURY, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- Physicians’ Education Resource®, LLC (PER®), a top educational resource for health care professionals to advance patient care, is excited to host a wide range of in-person + virtual continuing medical education (CME) satellite sessions at the 2024 Annual Oncology Meeting. The symposia will deliver exceptional content and practical education with sessions focused on lung cancer, hematologic cancers, disparities in cancer care and more. The sessions will take place at the Hilton Chicago in Chicago, Illinois, from May 31 to June 2, 2024.

Key Points: 
  • CRANBURY, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- Physicians’ Education Resource®, LLC (PER®), a top educational resource for health care professionals to advance patient care, is excited to host a wide range of in-person + virtual continuing medical education (CME) satellite sessions at the 2024 Annual Oncology Meeting.
  • The symposia will deliver exceptional content and practical education with sessions focused on lung cancer, hematologic cancers, disparities in cancer care and more.
  • “We are excited to host a diverse array of sessions at the 2024 Annual Oncology Meeting,” said Robert M. Goldsmith, senior vice president of corporate development at MJH Life Sciences®, PER’s parent company.
  • For event details and registration, please visit the PER Annual Oncology Meeting landing page .

Builders FirstSource Raises More Than $1 Million for The Leukemia & Lymphoma Society at Annual Charity Event

Retrieved on: 
木曜日, 5月 16, 2024
Urban Planning, REIT, Fund Raising, General Health, Foundation, Philanthropy, Other Construction & Property, Residential Building & Real Estate, Commercial Building & Real Estate, Other Manufacturing, Construction & Property, Health, Other Philanthropy, Manufacturing, Building Systems, Other Health, Oncology, Partnership, JELD-WEN, Patient, Boise Cascade, Commvault, LP, Bone marrow, Accenture, Audio, Friends, LLS, Meritage Homes Corporation, Leukemia & Lymphoma Society, Life, Builders FirstSource, Sport, Survivor, ODL, Cancer, Research, Builder, Firstsource, Leukemia, Georgia-Pacific, Trex, Cisco, Family, Hall, Pharmaceutical industry

Builders FirstSource proudly announces that its recent Annual Charity Event for The Leukemia & Lymphoma Society (LLS) successfully raised over $1 million for LLS, demonstrating the company's enduring commitment to fighting blood cancers.

Key Points: 
  • Builders FirstSource proudly announces that its recent Annual Charity Event for The Leukemia & Lymphoma Society (LLS) successfully raised over $1 million for LLS, demonstrating the company's enduring commitment to fighting blood cancers.
  • "We are deeply appreciative of the overwhelming support from our partners, which enabled us to make this significant contribution to The Leukemia & Lymphoma Society,” said Dave Rush, President and CEO of Builders FirstSource.
  • "Through the unwavering support and generosity of Builders FirstSource and its partners, we are empowered to advance towards a world without blood cancer.
  • Looking forward, Builders FirstSource aims to raise at least $2 million for LLS in 2024.

James Herring and John Gaffney join UBS Private Wealth Management in New York City

Retrieved on: 
金曜日, 4月 19, 2024
Finance, Consulting, Banking, Professional Services, Asset Management, Goldman Sachs, Army Reserve, Owen, Vanderbilt University, UBS, Leukemia, MBA, Leukemia & Lymphoma Society

UBS today announced that Private Wealth Advisors James Herring and John Gaffney will be joining the firm in New York City.

Key Points: 
  • UBS today announced that Private Wealth Advisors James Herring and John Gaffney will be joining the firm in New York City.
  • “On behalf of UBS, we’re very pleased to welcome James and John to the firm,” said Chris Amo, New York PWM Market Director at UBS Private Wealth Management.
  • James Herring joins UBS Private Wealth Management from Goldman Sachs, where he was a Managing Director with over 35 years of experience working with high-net-worth executives, non-profits and family offices.
  • John Gaffney joins UBS from Goldman Sachs where he spent five years focusing on holistic wealth management solutions for family offices and private wealth clients.

American Tinnitus Association Announces Patrick A. Lynch as New CEO

Retrieved on: 
木曜日, 4月 11, 2024
Leukemia & Lymphoma Society, Education, Rhode Island Bar Association, Hospice, Heart, Business administration, Research, American Tinnitus Association, Baptist Health South Florida, Tinnitus, TED (conference), Leukemia, Veteran, Suffolk University Law School, Big Brothers Big Sisters, MBA, ATA, Baptist Health, Growth

VIENNA, Va., April 11, 2024 /PRNewswire/ -- The American Tinnitus Association (ATA), the nation's only nonprofit dedicated exclusively to serving the tinnitus community, announced its hiring of Patrick A. Lynch, Esq., MBA, as its chief executive officer.

Key Points: 
  • VIENNA, Va., April 11, 2024 /PRNewswire/ -- The American Tinnitus Association (ATA), the nation's only nonprofit dedicated exclusively to serving the tinnitus community, announced its hiring of Patrick A. Lynch, Esq., MBA, as its chief executive officer.
  • With a lifelong commitment to community engagement and an exceptional track record in advocacy, fundraising, and nonprofit leadership, Lynch brings unparalleled expertise to ATA.
  • "It is an incredible honor to join the team at the American Tinnitus Association," said Lynch.
  • "More than 50 million people in the United States are affected directly by tinnitus, including 30 percent of all U.S. veterans.

Cyclists Take On America's Most Beautiful Bike Ride In Support Of Blood Cancer Patients

Retrieved on: 
水曜日, 4月 3, 2024
Diagnosis, Team In Training, Acute lymphoblastic leukemia, Bone marrow, University of Nevada, Reno, Leukemia & Lymphoma Society, Leukemia, Patient, SVP, Research, Perspiration, Cancer, University, RYE, Quality of life, LLS, Reader

RYE BROOK, N.Y., April 3, 2024 /PRNewswire/ -- Cyclists from across the country will help change the lives of blood cancer patients by gathering in Lake Tahoe on June 2, 2024 to participate in America's Most Beautiful Bike Ride. While working up a sweat and enjoying breathtaking views, riders' efforts will drive forward the work of The Leukemia & Lymphoma Society (LLS) to fund groundbreaking research, provide free patient support and assistance, and advocate on behalf of blood cancer patients and their families.

Key Points: 
  • In its efforts to reach and help all those impacted by a blood cancer diagnosis, LLS actively partners in communities across the country.
  • This year, LLS welcomes WVU Cancer Institute as America's Most Beautiful Bike's premier sponsor and new venue partner Tahoe Blue Event Center.
  • This year, America's Most Beautiful Bike Ride has chosen leukemia survivor Greg Carlson as the event's Honored Hero.
  • WHY: To support LLS and make an impact in the lives of all those affected by a blood cancer diagnosis.

Jasper Health and The Leukemia & Lymphoma Society® (LLS) Collaborate to Support Blood Cancer Patients

Retrieved on: 
水曜日, 3月 13, 2024
Quality of life, Education, Patient, LLS, Bone marrow, Leukemia & Lymphoma Society, Cancer, Leukemia, Caregiver, Birth control

This collaboration aims to provide comprehensive support and resources to blood cancer patients and their caregivers throughout their cancer experience journey.

Key Points: 
  • This collaboration aims to provide comprehensive support and resources to blood cancer patients and their caregivers throughout their cancer experience journey.
  • Jasper Health and LLS will work together to enhance access to free care navigation and support, education, and resources for blood cancer patients, ensuring that members have access to the latest information and support services tailored to their needs.
  • "We are thrilled to join forces with The Leukemia & Lymphoma Society to better serve individuals impacted by blood cancer," said Greg Orr, COO of Jasper Health.
  • "We are excited to partner with Jasper Health to expand our reach and support for blood cancer patients," said Gina Russo, Vice President of Patient Services & Strategic Partnerships for The Leukemia & Lymphoma Society.

Business & Community Leaders Join The Leukemia & Lymphoma Society's 2024 Visionaries Of The Year Annual Philanthropic Competition To Champion A World Without Blood Cancer

Retrieved on: 
火曜日, 3月 5, 2024
Leukemia, Bone marrow, Senior, LLS, Education, Quality of life, Volunteering, Leukemia & Lymphoma Society, Patient, Policy, Research, RYE, Visionaries, Birth control

Now underway for the 35th consecutive year, business and community leaders committed to improving the lives of those impacted by blood cancer are engaging in a little healthy competition through LLS's Visionaries of the Year campaign.

Key Points: 
  • Now underway for the 35th consecutive year, business and community leaders committed to improving the lives of those impacted by blood cancer are engaging in a little healthy competition through LLS's Visionaries of the Year campaign.
  • Participants of this have 10 weeks to raise funds that will directly support LLS's life-changing work.
  • LLS recognizes these inspiring individuals as "Visionaries," who are dedicated volunteers fundraising and creating awareness about blood cancer in their communities.
  • "Together, we will find cures and improve the quality of life for all those affected and ultimately create a world without blood cancer."

PredxBio Appoints Dr. Stanley Marks, Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors

Retrieved on: 
木曜日, 2月 15, 2024
Leukemia, Division, American Cancer Society, Doctor of Philosophy, Immunotherapy, UPMC Shadyside, Drug development, UPMC, Leukemia & Lymphoma Society, University, Patient, UPMC Hillman Cancer Center, Explainable artificial intelligence, Research, Cancer, Management

PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.

Key Points: 
  • PITTSBURGH, Feb. 15, 2024 /PRNewswire-PRWeb/ -- PredxBio, the industry leader in Spatial Biology and Explainable AI for predicting disease progression and response to therapy, proudly announces the appointment of Stanley M. Marks, M.D., Chairman of UPMC Hillman Cancer Center, as Chairman of its Board of Directors.
  • Dusty Majumdar, PhD, CEO of PredxBio
    "We are thrilled and privileged to announce the appointment of Dr. Marks as the Chairman of PredxBio's Board of Directors," expressed Dusty Majumdar, PhD, CEO of PredxBio.
  • "I am honored to serve as Chairman of the Board of Directors at PredxBio," commented Dr. Marks.
  • Supported by over 20 peer-reviewed publications, 4000+ citations, and numerous patents, PredxBio contributes significantly to improving cancer care.